Abstract
One hundred twenty-two patients were evaluated prospectively to determine the clinical efficacy of prophylactic cefazolin (Ancef∗) in cesarean section. The cefazolin was administered intravenously in a high-dose, short perioperative regimen. Postoperatively, each patient was evaluated for morbidity. Over all, the postoperative morbidity rate was reduced from 30 per cent in the placebo group to 18 per cent in the cefazolin group. More important, the infection rate associated with primary cesarean section was significantly lessened from 38 per cent in the placebo group to 16 per cent in the drug group (p < 0.025). In repeat cesarean sections, the postoperative morbidity rate was greater in the antibiotic-treated group (20 per cent) than in the placebo group (14 per cent). Of major importance, a predominant organism, Group D streptococcus, was encountered in the postoperative cultures of the cefazolin group.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
